A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Jul 2020.
- 24 Oct 2019 Status changed from active, no longer recruiting to recruiting.
- 12 Sep 2018 Planned End Date changed from 1 Jul 2020 to 31 Jul 2020.